Stacy Enxing Seng
Venture Partner

Stacy is a Venture Partner of LSV and assists the LSV medical device team with deal sourcing, due diligence, and portfolio company management. She joined the LSV team in March, 2016.

Stacy currently serves as an Independent Director for both public and venture-backed private companies in director and committee member roles. An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture.

Prior to Independent Director work, Stacy spent the last 25 years in medtech, most recently serving as the President of Covidien’s $1.7B Vascular Therapies business. Stacy joined Covidien following its $2.6B acquisition of ev3 Inc., a medical technology start-up success that Stacy co-created in 2000 with ev3’s founding team. Over the course of her career Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions, and under her operating leadership, a reputation of achieving world class customer and employee engagement.

Stacy’s earlier work in medtech included sales and marketing management roles with SCIMED/Boston Scientific and sales and product management roles with American Hospital Supply/Baxter.

Stacy currently serves as a non-executive Independent Director for Hill-Rom Holdings, Inc., (NYSE: HRC) as well as Sonova Holding AG (VTX: SOON). Additionally, Stacy serves as an Independent Director for Spirox, Inc. and Solace Therapeutics, both private venture-backed companies. Past Director appointments include FIRE 1 and CVI.


B.A. Public Policy, Michigan State University.
M.B.A. Harvard University